Glaucoma drug compliance linked to age

Article

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease.

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease, according to a report presented at the annual meeting of the French Society of Ophthalmology.

Florent Aptel, MD and colleagues asked patients to complete a questionnaire concerning non-observance of treatment schedules. In addition, visual field examinations were performed and patients were asked to apply eye drops in the same way as they would at home.

Twenty-four percent of patients admitted non-compliance and approximately 20% instilled their drops outside of the eye. The non-compliant patients were mainly younger or those with earlier stages of the disease. Those who had difficulty in applying the drops tended to be older, with poorer visual acuity and larger visual field defects.

Based on this data the researchers identified two typical patient groups. The first are the relatively young patients with early stage glaucoma, which does not have a significant impact on their life. These subjects are able to carry out the instillation properly but are likely to be less compliant. The second group comprises of the older patients who have more advanced glaucoma, which does have a significant impact on their day-to-day life. These are more compliant but have difficulties performing the instillation correctly, often allowing all or part of the medication to drop outside of the eye.

This study suggests that compliance and drug administration in glaucoma patients can be directly correlated to age and disease severity.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.